Remove takeda-pull-lung-cancer-med-exkivity-around-world-after-confirmatory-trial-flop
article thumbnail

Takeda to pull lung cancer med Exkivity around the world after confirmatory trial flop

Fierce Pharma

After a confirmatory trial flop this past summer, Takeda is calling it quits on its targeted non-small cell lung cancer (NSCLC) drug Exkivity. Takeda will work with the FDA to chart a voluntary withdrawal of Exkivity in the U.S.,

FDA 239